Botanix Pharmaceuticals acquires Sofpironium Bromide gel to treat excessive underarm sweating

Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel.

The product has been developed to treat axillary hyperhidrosis, which is a medical condition that results in excessive underarm sweating.

Mr Ippolito says the acquisition is a defining deal for Botanix, with Sofpironium Bromide the first and only new chemical entity developed for this condition.

Article:
https://smallcaps.com.au/botanix-acquires-novel-medical-dermatology-asset-treat-axillary-hyperhidrosis/

For more information on Botanix Pharmaceuticals:
https://smallcaps.com.au/stocks/BOT/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/